PHARMACLIQ LIMITED

Company Registration Number:
13172350 (England and Wales)

Unaudited micro entity accounts for the year ended 28 February 2023

Period of accounts

Start date: 01 March 2022

End date: 28 February 2023

PHARMACLIQ LIMITED

Contents of the Financial Statements

for the Period Ended 28 February 2023

Company Information - 3
Profit and Loss Account - 4
Balance sheet - 5
Footnotes to the Balance Sheet - 7

PHARMACLIQ LIMITED

Company Information

for the Period Ended 28 February 2023




Registered office: 71-75
Shelton Street
Covent Garden
London
GBR
WC2H 9JQ
Company Registration Number: 13172350 (England and Wales)

PHARMACLIQ LIMITED

Profit and Loss Account

for the Period Ended 28 February 2023


2023
£
13 months to
28 Feb 2022
£
Turnover 174,817 81,867
Income from coronavirus (COVID-19) business support grants 0 -
Other Income 0 -
Cost of Materials ( 59,848 ) -
Staff Costs ( 35,483 ) ( 21,099 )
Depreciation and Writeoffs ( 1,644 ) ( 1,094 )
Other charges ( 17,910 ) ( 13,146 )
Tax on Profit ( 11,387 ) ( 8,868 )
Profit or (Loss) for Period 48,545 37,660

PHARMACLIQ LIMITED

Balance sheet

As at 28 February 2023


2023
£
13 months to
28 Feb 2022
£
Called up share capital not paid: 1 1
Fixed Assets: 5,026 4,470
Current assets: 84,544 32,752
Prepayments and accrued income: 16,907 10,697
Creditors: amounts falling due within one year: ( 20,273 ) ( 10,260 )
Net current assets (liabilities): 81,178 33,189
Total assets less current liabilities: 86,205 37,660
Total net assets (liabilities): 86,205 37,660
Capital and reserves: 86,205 37,660

PHARMACLIQ LIMITED

Balance sheet continued

For the year ending 28 February 2023 the company was entitled to exemption under section 477 of the Companies Act 2006 relating to small companies.

The members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.

These accounts have been prepared and delivered in accordance with the provisions of the small companies regime applicable to micro-entities.

This report was approved by the board of directors on 28 November 2023
And Signed On Behalf Of The Board By:

Name: Modolapo Lawal
Status: Director

The notes form part of these financial statements

PHARMACLIQ LIMITED

Footnotes to the Financial Statements

for the Period Ended 28 February 2023

  • 1. Employee Information

    Average number of employees: 2

PHARMACLIQ LIMITED

Footnotes to the Financial Statements

for the Period Ended 28 February 2023

  • 2. Off balance sheet disclosure

    No